ArticleJournal of diabetes research2026
Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveHispanic individuals are disproportionately affected by type 2 diabetes (T2D) and face access limitations in diabetes technology utilization. Despite proven benefits, continuous glucose monitoring (CGM) use remains low among Hispanic adults with insulin-treated T2D. This study used a social-ecological model (SEM) framework to identify societal/policy, interpersonal/community, and individual level barriers to CGM access and adoption within this population.
methodsTwo focus groups were conducted in Spanish at the University of Miami (UM) with Hispanic adults (n = 16) with T2D. Inclusion criteria were age ≥18 years, HbA1c ≥8%, ≥1 daily insulin injection, and no CGM use in the past 2 years. The initial focus group was conducted to identify barriers to CGM initiation. At the end of the focus group, participants were provided with real-time CGMs for 30 days of use. After completing the wear period, the same participants returned for a follow-up focus group to explore factors related to CGM adoption and acceptance. Focus groups were analyzed using a thematic analysis, systematically coding and categorizing key concepts and ideas expressed by participants.
resultsThe mean age was 59.68 ± 13.37 years, and baseline HbA1c was 9.78 ± 1.14. Key barriers included high device costs, limited insurance coverage, alarm fatigue, and lack of culturally concordant provider guidance. Facilitators for CGM use included manufacturer discounts, peer modeling, and the desire to avoid fingersticks. After a 30-day CGM trial, most participants reported improved dietary awareness, glycemic control, and a strong desire for continued use.
conclusionThis pilot study provides novel insights into the experiences of the Hispanic population and highlights the complex interplay of societal, interpersonal, and individual-level factors influencing CGM use. Tailored interventions addressing these barriers are crucial for improving CGM utilization in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.